GLP-1 Therapy for Obesity & Cardiometabolic Disease — Summary

GLP-1 receptor agonists have transformed obesity treatment by targeting hormonal and metabolic dysfunction rather than willpower. Agents like semaglutide and tirzepatide demonstrate meaningful weight loss, reductions in cardiovascular risk, and strong metabolic benefits. Clinical trials such as STEP, SELECT, and SURMOUNT position GLP-1 therapies as foundational treatments in 2025.

Full PDF click HERE